CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
Ipilimumab, 3 mg +3 moredrug
Likely dose
Ipilimumab, 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01165216
NCT01165216Phase 1Completed
CompareCT.gov

Phase 1 Study of Ipilimumab (BMS-734016) in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer

Bristol-Myers Squibb·interventional·Posted Jul 19, 2010·Updated Jul 22, 2014

In Brief

A Phase 1 clinical trial evaluating Ipilimumab, 3 mg, Ipilimumab, 10 mg, and 2 other interventions for Non-Small Cell Lung Cancer. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The primary purpose of this study was to establish the recommended dose of ipilimumab administered in combination with paclitaxel and carboplatin in Japanese patients with nonsmall-cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 19, 2010
Enrollment StartSep 1, 2010
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.0 years ago

Interventions

Ipilimumab, 3 mgdrug

Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles

Ipilimumab, 10 mgdrug

IV injection, administered every 3 weeks for up to 6 cycles

Paclitaxeldrug

IV injection, 175 mg/m\^2, administered every 3 weeks for up to 6 cycles

Carboplatindrug

IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)